Clinuvel has commenced its INSPIRE (International SCENESSE® Pilot Repigmentation Evaluation) program to evaluate the use of its first-in-class drug SCENESSE® (afamelanotide) as a repigmentation therapy in vitiligo.
The first of these studies, CUV102, has completed, with treatment results released in December 2012.
Clinuvel has established this webpage to serve as a portal for all information relevant to this study and vitiligo more broadly. See this document for more details on participating in the INSPIRE program.
